vimarsana.com

Page 17 - தொழில்நுட்பம் கண்டுபிடிப்பு பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products

Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products News provided by Share this article Share this article SAN DIEGO and SHANGHAI, Dec. 15, 2020 /PRNewswire/  Singlera Genomics Inc. today announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. The new group of investors also include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the Series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures joined with follow-on investment. Singlera will utilize this round of financing mainly to expand the company s early cancer screening product research and development pipeline and focus on promoting product registration and commercialization, as well

Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products

December 15, 2020 SAN DIEGO and SHANGHAI, Dec. 15, 2020 /PRNewswire/  Singlera Genomics Inc. today announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. The new group of investors also include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the Series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures joined with follow-on investment. Singlera will utilize this round of financing mainly to expand the company s early cancer screening product research and development pipeline and focus on promoting product registration and commercialization, as well as expanding prospective studies into pan-cancer early screening.

Why JinkoSolar Holding Stock Popped This Morning

JinkoSolar Holding (NYSE:JKS) saw its stock soar in early trading on the NYSE this morning. As of 10:45 a.m. EST, Jinko shares remain up a healthy 8.2%. And yet, at least at first glance, the news doesn t look great. So what Early this morning, JinkoSolar Holding announced that its CEO, chief marketing officer, chief operating officer, chief human resources officer, and chief technology officer have all resigned effective immediately.   Image source: Getty Images. That sounds pretty bad, but as Jinko explained, all five of these resignations were conducted only to comply with certain business operations and independence requirements of the Shanghai Stock Exchange Science and Technology Innovation Board (the STAR Market ).

JinkoSolar Holding Appoints Chairman Xiande Li As CEO

JinkoSolar Holding Appoints Chairman Xiande Li As CEO WASHINGTON (dpa-AFX) - JinkoSolar Holding Co., Ltd. (JKS) announced Tuesday changes to its senior management team, in order to comply with certain business operations and independence requirements of the Shanghai Stock Exchange Science and Technology Innovation Board, in relation to the proposed listing of its principal operating subsidiary, Jinko Solar Co., Ltd. Kangping Chen, Gener Miao, Jiun-Hua Allen Guo, Shaoguo Ji and Dr. Hao Jin have resigned as chief executive officer, chief marketing officer, chief operating officer, chief human resources officer and chief technology officer of JinkoSolar, respectively, effective immediately, but will carry out their respective responsibilities at Jiangxi Jinko.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.